166 related articles for article (PubMed ID: 9055997)
1. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
Girard AE; Girard D; Gootz TD; Faiella JA; Cimochowski CR
Antimicrob Agents Chemother; 1995 Oct; 39(10):2210-6. PubMed ID: 8619569
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.
Thadepalli H; Chuah SK; Reddy U; Hanna N; Clark R; Polzer RJ; Gollapudi S
Antimicrob Agents Chemother; 1997 Sep; 41(9):1933-6. PubMed ID: 9303387
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection.
Onderdonk AB
Am J Surg; 1998 Dec; 176(6A Suppl):39S-45S. PubMed ID: 9935256
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
Brook I
Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of temafloxacin in a rat model of intra-abdominal abscess.
Thadepalli H; Hajji M; Perumal VK; Chuah SK; Gollapudi S
J Antimicrob Chemother; 1992 Jun; 29(6):687-92. PubMed ID: 1324241
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Thadepalli H; Chuah SK; Gollapudi S
Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection.
Alou L; Anta ML; Del Potro MG; Fuentes F; Balcabao IP; Gomez-Lus ML; Prieto J
Int J Antimicrob Agents; 1999 Jul; 12(2):135-9. PubMed ID: 10418758
[TBL] [Abstract][Full Text] [Related]
11. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
Brook I
Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Fu KP; Vince T; Bloom R; Gregory FJ; Hung PP
Drugs Exp Clin Res; 1987; 13(8):493-6. PubMed ID: 3322752
[TBL] [Abstract][Full Text] [Related]
13. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
Wells CL; Arland LA; Simmons RL; Rotstein OD
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.
Thadepalli H; Gollapudi SV; Chuah SK
Antimicrob Agents Chemother; 1986 Oct; 30(4):574-6. PubMed ID: 3539011
[TBL] [Abstract][Full Text] [Related]
15. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Goldstein EJ
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S106-11. PubMed ID: 12173118
[TBL] [Abstract][Full Text] [Related]
16. In-vitro susceptibility and in-vivo efficacy of antimicrobials in the treatment of intraabdominal sepsis in mice.
Brook I; Gillmore JD
J Antimicrob Chemother; 1993 Mar; 31(3):393-401. PubMed ID: 8486573
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic penetration of experimental intra-abdominal abscesses.
Galandiuk S; Lamos J; Montgomery W; Young S; Polk HC
Am Surg; 1995 Jun; 61(6):521-5. PubMed ID: 7762902
[TBL] [Abstract][Full Text] [Related]
18. The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli.
Brook I; Ledney GD
J Antimicrob Chemother; 1994 Feb; 33(2):243-52. PubMed ID: 8182005
[TBL] [Abstract][Full Text] [Related]
19. Effect of Bacteroides fragilis on mortality induced by Escherichia coli in an experimental infection treated with cefotaxime, aztreonam or gentamicin.
Soriano F; Ponte C; Santamaría M; Castilla C
J Antimicrob Chemother; 1989 Mar; 23(3):383-8. PubMed ID: 2659565
[TBL] [Abstract][Full Text] [Related]
20. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.
Edelstein PH; Edelstein MA; Ren J; Polzer R; Gladue RP
Antimicrob Agents Chemother; 1996 Feb; 40(2):314-19. PubMed ID: 8834872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
